Progression-free survival prolonged with sacituzumab govitecan plus pembrolizumab in triple-negative breast cancer

For patients with previously untreated, programmed death ligand 1 (PD-L1)-positive, locally advanced unresectable or metastatic triple-negative breast cancer (TNBC), sacituzumab govitecan plus pembrolizumab yields significantly longer…

Continue Reading

News Source: medicalxpress.com